Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

60.08 +5.26 (+9.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,368,142
Open 55.90
Bid (Size) 61.55 (5)
Ask (Size) 61.60 (3)
Prev. Close 54.82
Today's Range 55.79 - 60.13
52wk Range 30.04 - 63.68
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death

Performance

YTD
+45.0%
+45.0%
1 Month
+42.7%
+42.7%
3 Month
+72.2%
+72.2%
6 Month
+45.5%
+45.5%
1 Year
+9.2%
+9.2%

More News

Read More
10 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Cathie Wood-Led Ark Launches Buffer ETFs For Its Flagship ARKK, Analyst Says It's Like Diet Soda — 50% Loss Protection, But There's A Catch
Via Benzinga
Topics ETFs
2 Beaten-Down Stocks With Massive Upside Potential
Via The Motley Fool
2 Growth Stocks to Buy Hand Over Fist in July
Via The Motley Fool
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Via The Motley Fool
44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy
Via Benzinga
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Via Investor's Business Daily
Topics Government
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
Via Investor's Business Daily
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It
Via Benzinga
Topics Artificial Intelligence
The Best Stocks to Invest $1,000 in Right Now
Via The Motley Fool
Topics Government World Trade
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Via The Motley Fool
Topics Economy
5 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Topics Artificial Intelligence
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
Via The Motley Fool
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Via The Motley Fool
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
Via MarketBeat
Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?
Via The Motley Fool
2 Biotech Stocks That Are Screaming Buys in May
Via The Motley Fool
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?
Via The Motley Fool
3 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Topics Artificial Intelligence World Trade

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 60.08
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 07/09/25 04:00 PM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 4.74B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.